Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup analysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).

Ming Gao,Yihebali Chi,Xiangqian Zheng,Dapeng Li,Pingzhang Tang,Zhengang Xu,Xiaohong Chen,Minghua Ge,Yuan Zhang,Zhuming Guo,Jun Wang,Jie Chen,Jiewu Zhang,Ying Cheng,Zhendong Li,Hui Liu,Jianwu Qin,Jingqiang Zhu,Ruochuan Cheng

Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup analysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).

2020

Ming Gao
Yihebali Chi
Xiangqian Zheng
Dapeng Li
Pingzhang Tang
Zhengang Xu
Xiaohong Chen
Minghua Ge
Yuan Zhang
Zhuming Guo
Jun Wang
Jie Chen
Jiewu Zhang
Ying Cheng
Zhendong Li
Hui Liu
Jianwu Qin
Jingqiang Zhu
Ruochuan Cheng

6527Background: Anlotinib is a newly developed TKI achieved a nearly 2-fold PFS prolongation in a randomized, placebo-controlled phase 2b trial (NCT02586350) for MTC, the results of which were firs...

Keywords:

Subgroup analysis
Oncology
tumor size
thyroid carcinoma
Internal medicine
Medullary cavity
group performance
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations